4:35 PM
 | 
Jan 04, 2013
 |  BC Extra  |  Clinical News

Amicus gains on additional Phase II Pompe's disease data

Amicus Therapeutics Inc. (NASDAQ:FOLD) gained $0.28 (8%) to $3.58 on Friday after reporting additional data from the fourth and final cohort of the Phase II Study 010 trial of AT2220 for Pompe's disease. Additional...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >